Eletriptan is a second-generation triptan drug used to treat migraine headaches. It is marketed under the brand name Relpax and comes in the form of eletriptan hydrobromide. It serves as an abortive drug, stopping an already-in-progress migraine headache.
Treatment for migraine headache symptoms with eletriptan (severe throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Eletriptan belongs to the group of drugs known as selective serotonin receptor agonists.
It eases pain, nausea, vomiting, and other migraine symptoms, such as sensitivity to light and sound. Eletriptan use for ten or more days each month, whether alone or in conjunction with other migraine medications, may exacerbate headaches.
The Global Eletriptan Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
The most recent “triptan” to be authorised for the treatment of migraine headaches is eletriptan. It is the sixth company to enter this competitive market. Pfizer will market “Relpax” as eletriptan, a selective 5-hydroxytryptamine (serotonin) 1B/1D receptor (5-HT1B, 5-HT1D) agonist.
Adults suffering from acute migraine with or without aura should take eletriptan. Eletriptan has a strong bioavailability of 50%, a high lipid solubility, and a good elimination half-life of 4-6 hours. It also has a sluggish rate of dissociation from 5-HT1D receptors and a very low affinity for HT2 receptors in coronary arteries.
At two hours, eletriptan was said to have a better response than sumatriptan. In comparison to sumatriptan (40–80 mg), eletriptan (40–80 mg) produced headache responses ranging from 64-67% to 50–53%. (50 mg-100 mg). Both 19-18% and 31-37% of respondents reported no pain.
A crowded “triptan” market is entered by eletriptan. Given that the higher and more effective dose of eletriptan was not approved out of concern about side effects, it does not appear to offer any clinical advantages over currently available “triptans.”
Eletriptan must be avoided for at least 72 hours after taking any powerful CYP3A4 inhibitors because CYP3A4 is the enzyme responsible for metabolising the drug. They include ritonavir, nelfinavir, nefazodone, troleandomycin, ketoconazole, and itraconazole.
Eletriptan is thought to lessen brain-circumfering blood vessel enlargement. The head discomfort of a migraine attack goes hand in hand with this swelling.
Eletriptan reduces pain and other symptoms including nausea and sensitivity to light and sound by preventing the release of chemicals from nerve endings that cause these symptoms. These actions are believed to aid in the symptom alleviation provided by eletriptan.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.